FDA programs
NDA vs BLA vs ANDA: FDA application types explained
NDA vs BLA vs ANDA explained: what each FDA application covers, how 505(b)(1), 505(b)(2), 505(j), 351(a) and 351(k) differ, and which exclusivity applies.
By the All In Biotech editorial team · Published November 18, 2026 · 6 min read
An NDA (new drug application) is how a company asks FDA to approve a new drug, usually a small-molecule medicine. A BLA (biologics license application) is the equivalent for biological products such as antibodies, vaccines and other proteins. An ANDA (abbreviated new drug application) is the generic pathway: the applicant shows its product matches an approved drug and does not repeat the original clinical trials.
The five application types
US law has two statutes for medicines. Drugs are approved under section 505 of the Federal Food, Drug, and Cosmetic Act (FD&C Act). Biological products are licensed under section 351 of the Public Health Service Act (PHS Act). Each statute has a full pathway and an abbreviated one, and the drug side has a middle route.
| Application | Statute | Used for | Evidence relied on |
|---|---|---|---|
| NDA, 505(b)(1) | FD&C Act | New drugs, usually new molecules | The applicant's own studies, or studies it has a right to use |
| NDA, 505(b)(2) | FD&C Act | Changes to known drugs: new formulation, dose, route, salt, combination or use | At least partly on studies the applicant did not conduct, such as literature or FDA's findings for an approved drug |
| ANDA, 505(j) | FD&C Act | Generic copies of approved drugs | Sameness to a reference listed drug and bioequivalence |
| BLA, 351(a) | PHS Act | New biological products | Full data showing the product is safe, pure and potent |
| BLA, 351(k) | PHS Act | Biosimilar and interchangeable biologics | Biosimilarity to a reference product |
NDA: 505(b)(1) and 505(b)(2)
A new drug application contains everything FDA needs to decide whether a drug is safe and effective for its proposed use: clinical trial results, animal studies, manufacturing and quality information (chemistry, manufacturing and controls) and proposed labeling.
A 505(b)(1) NDA is the classic full application. The applicant ran the studies itself or has a right of reference to them. Most new molecular entities go this way.
A 505(b)(2) NDA also contains full reports showing safety and effectiveness, but some of the evidence comes from studies the applicant did not conduct and has no right to use. That can be published literature or FDA's previous finding that an approved drug is safe and effective. Common examples:
- An extended-release version of an existing drug.
- A new salt or route of administration, such as an injection of a drug sold as a tablet.
- A fixed-dose combination of two approved drugs.
- A new indication for a known molecule supported partly by literature.
A 505(b)(2) application still needs bridging data, often bioavailability studies, to link the new product to the evidence it relies on. Like an ANDA, it must address patents listed for the drug it relies on.
ANDA: the generic pathway
The abbreviated new drug application was created by the Drug Price Competition and Patent Term Restoration Act of 1984, known as Hatch-Waxman. A generic applicant must show that its product has the same active ingredient, strength, dosage form, route of administration and, with limited exceptions, labeling as a reference listed drug, and that it is bioequivalent. It does not repeat the reference drug's clinical trials.
Generics approved this way receive a therapeutic equivalence rating in the Orange Book, which pharmacists use to decide when products can be substituted. The Orange Book vs Purple Book guide explains the codes.
ANDAs also carry the patent machinery of Hatch-Waxman:
- The applicant certifies against each patent listed for the reference drug. A paragraph IV certification says the patent is invalid or will not be infringed.
- If the brand company sues within 45 days of notice, FDA approval is generally stayed for up to 30 months.
- The first applicant to file a substantially complete paragraph IV ANDA can earn 180 days of generic exclusivity.
BLA: 351(a) and 351(k)
A biologics license application covers products made from living systems: monoclonal antibodies, therapeutic proteins, vaccines, blood products, and cell and gene therapies. Instead of "safe and effective", the PHS Act standard is that the product is safe, pure and potent, and the license also covers the facility and manufacturing process. FDA's BLA overview describes the contents.
A 351(a) BLA is the full application for a new biologic. A 351(k) BLA is the abbreviated pathway for biosimilars, created by the Biologics Price Competition and Innovation Act of 2009 (BPCI Act). The applicant shows the product is highly similar to a reference product, with no clinically meaningful differences in safety, purity and potency. A biosimilar can also be approved as interchangeable, which allows pharmacy substitution where state law permits. See biosimilars and interchangeable biologics for how to find them.
Which FDA center reviews what
- CDER reviews NDAs, ANDAs and BLAs for therapeutic biologics such as monoclonal antibodies and most therapeutic proteins.
- CBER reviews BLAs for vaccines, blood products, and cell and gene therapies.
The 2020 transition
Some protein products, such as insulins, human growth hormone and hyaluronidase, were historically approved as NDAs. Under the BPCI Act, those applications were deemed to be BLAs on March 23, 2020. That is why some older protein drugs now carry BLA numbers and appear in the Purple Book.
Exclusivity by application type
Exclusivity is a period of protection granted by FDA on approval, separate from patents. The main periods, set by statute:
| Exclusivity | Length | Applies to | What it blocks |
|---|---|---|---|
| New chemical entity | 5 years | NDA for a new active moiety | ANDA and 505(b)(2) submissions, which can be filed after 4 years with a paragraph IV certification |
| New clinical investigation | 3 years | NDA or supplement supported by new essential clinical studies | Approval of ANDAs and 505(b)(2)s for that change |
| Orphan drug | 7 years | Approved orphan use, NDA or BLA | Approval of the same drug for the same use |
| Pediatric | 6 months added | Existing exclusivities and patents, after FDA-requested pediatric studies | Extends other protections |
| Reference biologic | 12 years | 351(a) BLA | Approval of 351(k) biosimilars; submission is blocked for the first 4 years |
| First generic | 180 days | First paragraph IV ANDA filer | Approval of later ANDAs |
FDA's patents and exclusivity FAQ covers the details and exceptions.
Supplements: changes after approval
An approved application changes over its life through supplements. Efficacy supplements add a new indication, population or dosing regimen. Manufacturing and labeling supplements handle other changes. A supplement keeps the original application number, which is why a drug like Keytruda shows one BLA with 110 approved uses on this site, counting the original approval and efficacy supplements, as of November 2026.
How many of each
From the Drugs@FDA data on this site, as of November 2026:
- 5,899 brand-name applications in the catalog: 5,412 NDAs and 487 BLAs. 3,248 have at least one product still marketed.
- Drugs@FDA itself holds about 23,000 ANDAs. Generic applications are not in this site's catalog.
- Of 48 2026 novel approvals matched to Drugs@FDA records, 11 were BLAs.
Drugs@FDA covers CDER, so most vaccines, blood products and cell and gene therapies, which are CBER BLAs, do not appear.
Reading an application number
Application numbers tell you the type. On this site, each drug page uses the prefix and number from Drugs@FDA:
- NDA209637 is Ozempic (semaglutide), a drug application.
- NDA215866 is Mounjaro (tirzepatide), also an NDA, since peptides of 40 amino acids or fewer are regulated as drugs.
- BLA125514 is Keytruda (pembrolizumab), a monoclonal antibody.
The 505(b) subtype is not shown in the application number. The approval letter and review documents in Drugs@FDA usually state whether an NDA was submitted under 505(b)(2). The Drugs@FDA search guide walks through finding approval letters and review documents.
Frequently asked questions
- What is the difference between an NDA and a BLA?
- An NDA is used for drugs, mostly chemically made small molecules, under section 505 of the Federal Food, Drug, and Cosmetic Act. A BLA is used for biological products such as antibodies, vaccines and other proteins, under section 351 of the Public Health Service Act.
- What is an ANDA?
- An abbreviated new drug application is the generic drug pathway under section 505(j). The generic shows it is the same as an approved reference drug and bioequivalent to it, instead of repeating the clinical trials.
- What is a 505(b)(2) application?
- It is an NDA that relies at least in part on studies the applicant did not conduct and has no right to use, such as published literature or FDA's earlier findings for an approved drug. It is often used for new formulations, doses or combinations of known drugs.
- Are biosimilars approved through an ANDA?
- No. Biosimilars use a separate abbreviated pathway, the 351(k) BLA, created by the Biologics Price Competition and Innovation Act of 2009.
For information only, not medical, legal or investment advice. Facts about FDA and CMS programs are current as of the publication date; check the linked official source for changes.